Louis J. Picker - Vaccines

Author Information

Louis J. Picker is a prominent researcher affiliated with the Vaccine and Gene Therapy Institute at Oregon Health & Science University in Beaverton, Oregon, United States. His work predominantly focuses on immunology and virology, with significant contributions to the study of HIV and SIV vaccines. His research is crucial in understanding the immune responses that can be leveraged for developing effective vaccines.

Research Contributions

Louis J. Picker has made substantial contributions to the field of vaccine research, particularly in the context of HIV and SIV. His recent works include exploring the effects of rapamycin on CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques, the potential of ingenol-based protein kinase C agonists in inducing HIV and SIV RNA transcription, and the efficacy of RhCMV/SIV vaccines. His research is instrumental in advancing knowledge on vaccine efficacy and immune responses, providing valuable insights into potential therapeutic strategies.

Aliases

Louis J. Picker is known by several aliases in academic publications, including L J Picker, Louis J Picker, L Picker, and Louis Picker. These variations are used interchangeably in his published works.

Publication and Citation Metrics

Metric	Value
Citation Count	38,398
H-index	90
Paper Count	293

Publications:

Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.

DOI: 10.1172/JCI156063

Year: 2022

The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription

DOI: 10.1371/journal.ppat.1010245

Year: 2022

BFF and cellhashR: Analysis Tools for Accurate Demultiplexing of Cell Hashing Data.

DOI: 10.1093/bioinformatics/btac213

Year: 2022

Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

DOI: 10.1128/JVI.02393-20

Year: 2021

Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy

DOI: 10.1371/journal.ppat.1009278

Year: 2021

Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques

DOI: 10.1016/j.omtm.2021.06.008

Year: 2021

Sustained IL-15 response signature predicts RhCMV/SIV vaccine efficacy

DOI: 10.1101/2021.01.11.426199

Year: 2021

Identification and Characterization of Antigen-Specific CD8+ T Cells Using Surface-Trapped TNF-α and Single-Cell Sequencing

DOI: 10.4049/jimmunol.2100535

Year: 2021

Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy

DOI: 10.1126/sciimmunol.abg5413

Year: 2021

HLA-E–restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities

DOI: 10.1126/sciimmunol.abg1703

Year: 2021

How Do Molecular Diagnostics Assist in Post-Market Surveillance?

What Are the Challenges in HCC Prevention?

How Can Healthcare Providers Ensure Data Privacy in Telemedicine?

How Are Vaccines Developed and Deployed During an Outbreak?

How Do Genetically Engineered Vaccines Work?

What is a Fractional Dose?

How Do These Drugs Affect Vaccine Efficacy?

What are the Key Factors Affecting Vaccine Efficacy?

What is the Importance of Hygiene in Vaccination?

How are Cytokine Storms Treated?

Partnered Content Networks

Relevant Topics